Eight new items will be added to Clariant’s portfolio of high-performing pharmaceutical components in an effort to promote the development of safe and efficient medications.
Excipients for diverse applications, such as parenteral formulations, sensitive active pharmaceutical ingredients, or applications requiring a colorless final formulation, are included in the enlarged range.
To talk about these goods and solutions, our specialists will be accessible at Stand 6G21 (zone Excipients) at the Fiera Milano in Italy.
Clariant is thrilled to showcase its most recent line of medical goods at the CPHI exhibition, which takes place in Milan, Italy, from October 8–10, 2024.
“We’ve expanded on our track record of success by offering a wider range of solutions to help the manufacturing and development of medicines for the industry’s emerging technologies, such the injectables market. With our new excipients, we address the market’s need for low endotoxin and highly purified solubilizers,” comments Vaios Barlas, Global Head of Health Care at Clariant.
Introducing VitiPureTM LEX 3350 S, VitiPure LEX 4000 S, and Polyglykol 1450 S, Clariant addresses issues with the administration and bioavailability of active pharmaceutical ingredients (APIs).
For clients that need precise control over the microbial load in their formulations, VitiPure LEX is a product range. These co-solvents have been refined for safe usage with a range of APIs, including those with limited water solubility, and for sensitive applications.
VitiPure LEX 3350 S and VitiPure LEX 4000 S not only surpass the general pharmacopoeia monograph requirements, but they have also been risk-assessed in their production for their use as excipients in parenteral applications. In addition to the general monograph requirements, specific microbiological aspects have also been certified.
Polyglykol 1450 S is an alternative polyethylene glycol co-solvent specified according to the current USP-NF monograph, which is additionally meeting the monoethylene and diethylene glycol limits recommended by the corresponding FDA guideline on this topic. Polyglykol 1450 S is produced under IPEC GMP conditions in the form of flakes, which allows easier handling during production. This product surpasses current international pharmacopeia requirements